Chiesi Logo - 1.Primary (1).png
Patients With COPD May Soon Benefit From the Chiesi Farmaceutici's Investigation Into a Fixed Triple Combination ICS/LABA/LAMA
June 07, 2016 08:00 ET | Chiesi USA, Inc.
PARMA, ITALY--(Marketwired - June 07, 2016) - Chiesi is the first Company to complete 2 multicenter long-term clinical studies with a fixed triple combination for COPDThe preliminary results of the...
Chiesi Logo - 1.Primary (1).png
An Extrafine ICS/LABA Combination Decreases COPD Exacerbations More Than LABA/LAMA: a Comparative Analysis Versus Bronchodilator Monotherapy
May 18, 2016 08:00 ET | Chiesi USA, Inc.
PARMA, ITALY--(Marketwired - May 18, 2016) -  In the treatment of chronic obstructive pulmonary disease (COPD) the combination of inhaled corticosteroids (ICS) and long acting bronchodilators...
Chiesi Logo - 1.Primary (1).png
Chiesi to Acquire 3 Hospital Products - Kengreal(R), Cleviprex(R), Argatroban for Injection
May 09, 2016 07:00 ET | Chiesi USA, Inc.
PARMA, ITALY--(Marketwired - May 09, 2016) -  Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have agreed to acquire...
Chiesi Logo - 1.Primary (1).png
80 Years of Innovation and Success in Healthcare: Chiesi Reports Significant International Growth in 2015
March 30, 2016 09:15 ET | Chiesi USA, Inc.
PARMA, ITALY--(Marketwired - March 30, 2016) - Chiesi Farmaceutici generated just under EUR1.5bn in revenue in 2015, a year-on-year increase of almost 10%. The...
Chiesi Logo - 1.Primary (1).png
Chiesi USA, Inc. Certified as One of the Top Employers USA 2016
February 10, 2016 07:00 ET | Chiesi USA, Inc.
CARY, NC--(Marketwired - February 10, 2016) - Chiesi USA, Inc. announced today that the Top Employers Institute has named the company a Top Employer in the United States for 2016. The Top...
Chiesi Logo - 1.Primary (1).png
Chiesi USA Presents: Pioneering Innovative Research and Philanthropy in the Neonatal Community
February 20, 2015 11:06 ET | Chiesi USA, Inc.
ORLANDO, FL--(Marketwired - February 20, 2015) - Chiesi USA, dedicated to assisting with the advancement of neonatal research, hosted a complimentary seminar to provide a glimpse of the latest...
Chiesi Logo - 1.Primary (1).png
Chiesi USA Partners With March of Dimes for Prematurity Awareness Month
November 13, 2014 09:02 ET | Chiesi USA
CARY, NC--(Marketwired - Nov 13, 2014) - Chiesi USA, dedicated to assisting with the advancement of neonatal research and the treatment of preterm infant Respiratory Distress Syndrome (RDS), has...
Chiesi Logo - 1.Primary (1).png
Cornerstone Therapeutics Inc. Announces Name Change to Chiesi USA, Inc.
April 28, 2014 11:41 ET | Cornerstone Therapeutics
CARY, NC--(Marketwired - Apr 28, 2014) -  Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty...
Chiesi Logo - 1.Primary (1).png
Digestive Care, Inc. Donates Year-Long Supply of PERTZYE(R) (Pancrelipase) to Cystic Fibrosis Patients in El Salvador
March 10, 2014 09:05 ET | Cornerstone Therapeutics
BETHLEHEM, PA--(Marketwired - Mar 10, 2014) - Digestive Care, Inc. (DCI), the manufacturer of PERTZYE® (pancrelipase) and its marketing partner in the U.S. cystic fibrosis (CF) market,...
Chiesi Logo - 1.Primary (1).png
Cornerstone Therapeutics Inc. Stockholders Approve Merger
February 03, 2014 14:24 ET | Cornerstone Therapeutics
CARY, NC--(Marketwired - Feb 3, 2014) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (the "Company" or "Cornerstone"), a specialty pharmaceutical company focused on commercializing products for the...